Investing.com - Financial Markets Worldwide

CStone Pharmaceuticals (2616)

Hong Kong
Currency in HKD
6.89
+0.02(+0.29%)
Closed·
2616 Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
2616 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
6.707.50
52 wk Range
1.6313.15
Key Statistics
Edit
Bid/Ask
6.89 / 6.90
Prev. Close
6.87
Open
7.08
Day's Range
6.7-7.5
52 wk Range
1.63-13.15
Volume
23.97M
Average Volume (3m)
22.26M
1-Year Change
304.12%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2616 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
9.40
Upside
+36.38%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 13
Stock generally trades with high price volatility
Unlock InvestingPro

CStone Pharmaceuticals News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

CStone Pharmaceuticals Company Profile

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma. The company’s products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
131
Market
Hong Kong

Compare 2616 to Peers and Sector

Metrics to compare
2616
Peers
Sector
Relationship
P/E Ratio
−24.7x−9.0x−0.7x
PEG Ratio
0.15−0.060.00
Price/Book
29.6x2.7x2.6x
Price / LTM Sales
46.1x8.9x3.4x
Upside (Analyst Target)
36.8%24.8%37.6%
Fair Value Upside
Unlock−2.2%5.3%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.40
(+36.38% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-0.21 / --
Revenue / Forecast
49.45M / --
EPS Revisions
a
a
Unlock
Last 90 days

2616 Income Statement

FAQ

What Stock Exchange Does CStone Trade On?

CStone is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for CStone?

The stock symbol for CStone is "2616."

What Is the CStone Market Cap?

As of today, CStone market cap is 10.17B.

What Is CStone's Earnings Per Share (TTM)?

The CStone EPS (TTM) is -0.29.

From a Technical Analysis Perspective, Is 2616 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has CStone Stock Split?

CStone has split 0 times.

How Many Employees Does CStone Have?

CStone has 131 employees.

What is the current trading status of CStone (2616)?

As of 17 Oct 2025, CStone (2616) is trading at a price of 6.89, with a previous close of 6.87. The stock has fluctuated within a day range of 6.70 to 7.50, while its 52-week range spans from 1.63 to 13.15.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.